Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.

Although recombinant human erythropoietin (rhEpo) has been shown to be neuroprotective in experimental and clinical studies,1,2 prophylactic early high-dose rhEpo did not improve neurodevelopment among 2-year-olds who had been born very preterm in a randomized clinical trial.3 We report the prespecified secondary neurodevelopmental outcomes of the trial cohort at early school age.